Publications by authors named "Eddie Stenehjem"
Article Synopsis
- The study evaluated how urgent care clinicians prescribe antibiotics for conditions like sinusitis, acute otitis media, and pharyngitis, focusing on the choice of first-line antibiotics and their recommended durations of therapy.
- Conducted within the Intermountain Health network over one year, the research analyzed clinician practices and the factors influencing prescription patterns using descriptive statistics and modeling techniques.
- Results showed that first-line antibiotic selection was 75%, with variability based on condition; AOM had the highest selection rate (83%), while sinusitis had the lowest (69%). The study suggests a need for continued efforts to optimize antibiotic prescribing.
Background: Accurate methods of identifying patients with COVID-19 who are at high risk of poor outcomes has become especially important with the advent of limited-availability therapies such as monoclonal antibodies. Here we describe development and validation of a simple but accurate scoring tool to classify risk of hospitalization and mortality.
Methods: All consecutive patients testing positive for SARS-CoV-2 from March 25-October 1, 2020 within the Intermountain Healthcare system were included.
Background: Safe hospital discharge on parenteral antibiotic therapy is challenging for people who inject drugs (PWID) admitted with serious bacterial infections (SBI). We describe a Comprehensive Care of Drug Addiction and Infection (CCDAI) program involving a partnership between Intermountain Healthcare hospitals and a detoxification facility (DF) to provide simultaneous drug recovery assistance and parenteral antibiotic therapy (DRA-OPAT).
Methods: The CCDAI program was evaluated using a pre-/poststudy design.
Background: Neutralizing monoclonal antibodies (MAbs) are a promising therapy for early coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed in a real-world setting.
Methods: In this quasi-experimental pre-/postimplementation study, we estimated the effectiveness of MAb treatment within 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The primary outcome was a composite of emergency department visits or hospitalizations within 14 days of positive test.
Background: A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. However, clinical criteria specifically to define COVID-19-associated hyperinflammatory syndrome (cHIS) have not been established. We aimed to develop and validate diagnostic criteria for cHIS in a cohort of inpatients with COVID-19.
View Article and Find Full Text PDF